Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

861
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
861

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generalized environmental fear hypothesis and the effects of schematic restructuring in autism.

Frontiers in psychiatry·2026
Same author

Isolated mydriasis from ipsilateral internal carotid artery aneurysm.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2026
Same author

Factors Associated With Frequency and Hours of Daily Hearing Aid Use in the United States.

Laryngoscope investigative otolaryngology·2026
Same author

Genomic Enrichment and Functional Impact of TP53 and CYLD Alterations in Recurrent and Metastatic HPV-Associated Head and Neck Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Spatiotemporal analysis of human response to wildfire events and PM2.5 exposure.

American journal of epidemiology·2026
Same author

Unearthing soil biodiversity through collaborative genomic research and education.

Nature genetics·2025
Same journal

Mechanistic constraints in dengue severity: a systematic review with evidence stratification and agent-based evaluation of logical sufficiency.

Frontiers in immunology·2026
Same journal

Circadian control of immune homeostasis in cardiovascular health and disease.

Frontiers in immunology·2026
Same journal

An IHC-derived TLS-CD8-macrophage immune niche score predicts major pathological response to neoadjuvant chemoimmunotherapy in resectable NSCLC.

Frontiers in immunology·2026
Same journal

AF6 orchestrates macrophage polarization via JAK2-STAT3 signaling and supports intestinal regeneration by stimulating stem cell proliferation.

Frontiers in immunology·2026
Same journal

Restoring immune homeostasis in the spinal microenvironment: targeting mechano-inflammation and immunometabolic reprogramming.

Frontiers in immunology·2026
Same journal

A self-perpetuating neuron-intrinsic GSDMD-mtDNA-AIM2 inflammasome axis drives neuronal pyroptosis and cognitive impairment after traumatic brain injury.

Frontiers in immunology·2026
See all related articles

Related Experiment Video

Updated: Dec 13, 2025

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

9.0K

Development of Spherical Nucleic Acids for Prostate Cancer Immunotherapy.

Lei Qin1, Shuya Wang2, Donye Dominguez1

  • 1Division of Hematology/Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.

Frontiers in Immunology
|August 1, 2020
PubMed
Summary
This summary is machine-generated.

Novel Immunostimulatory Spherical Nucleic Acid (IS-SNA) nanostructures improve prostate cancer immunotherapy. Presenting antigens and adjuvants together on the surface enhances immune responses and antitumor efficacy.

Keywords:
CpGImmunostimulatory Spherical Nucleic Acids (IS-SNAs)immunotherapyprostate cancervaccines

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.6K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.1K

Related Experiment Videos

Last Updated: Dec 13, 2025

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

9.0K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.6K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.1K

Area of Science:

  • Oncology
  • Immunology
  • Nanotechnology

Background:

  • Therapeutic cancer vaccination for prostate cancer shows limited efficacy.
  • Current strategies require optimization for improved antitumor immune responses.

Purpose of the Study:

  • To develop and evaluate Immunostimulatory Spherical Nucleic Acid (IS-SNA) nanostructures for prostate cancer immunotherapy.
  • To investigate the impact of structural antigen and adjuvant positioning on IS-SNA efficacy.

Main Methods:

  • Designed hybrid model (HM) IS-SNAs with surface-presented antigens and CpG adjuvants.
  • Compared HM IS-SNAs with encapsulated model (EM) IS-SNAs and linear admixtures in syngeneic mouse models.
  • Assessed cytotoxic T lymphocyte (CTL) responses and antitumor efficacy.

Main Results:

  • HM IS-SNAs induced stronger antigen-specific CTL-mediated killing than EM IS-SNAs or linear admixtures.
  • HM IS-SNAs enhanced co-delivery of CpG and antigen to dendritic cells, improving cross-priming of CD8+ T cells.
  • Vaccination with HM IS-SNAs demonstrated more effective antitumor immune responses in two prostate cancer models.

Conclusions:

  • The structural arrangement of antigens and adjuvants within IS-SNAs is critical for immunotherapy efficacy.
  • Surface presentation of both components in HM IS-SNAs optimizes antitumor immune responses.
  • IS-SNAs represent a promising platform for enhancing cancer immunotherapy.